AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas
详细信息 查看全文
- 作者：Caitlin D. May ; Jeannine Garnett ; XiaoYan Ma ; Sharon M. Landers…
- 关键词：AXL ; Receptor tyrosine kinase ; Liposarcoma ; Soft tissue sarcoma
- 刊名：BMC Cancer
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：15
- 期：1
- 全文大小：3,113 KB
- 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
- 出版者：BioMed Central
- ISSN：1471-2407
文摘
Background AXL is a well-characterized, protumorigenic receptor tyrosine kinase that is highly expressed and activated in numerous human carcinomas and sarcomas, including aggressive subtypes of liposarcoma. However, the role of AXL in the pathogenesis of well-differentiated (WDLPS), dedifferentiated (DDLPS), and pleomorphic liposarcoma (PLS) has not yet been determined.